We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mucosis Appoints Thomas Johnston as Chief Business Officer
News

Mucosis Appoints Thomas Johnston as Chief Business Officer

Mucosis Appoints Thomas Johnston as Chief Business Officer
News

Mucosis Appoints Thomas Johnston as Chief Business Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mucosis Appoints Thomas Johnston as Chief Business Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mucosis B.V. has announced the appointment of Thomas Johnston as Chief Business Officer. In this role he will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.

Mr. Johnston joins Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea.

Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger.

Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

“Tom has more than 15 years of business development experience and an in-depth understanding of the vaccine and biotechnology space. Therefore we are very pleased to welcome him to our team” said Govert Schouten, Chief Executive Officer of Mucosis.

Schouten continued, “Through this appointment, we extend our business development reach for the success of our Mimopath™-based vaccine candidates."

Tom Johnston added: “I am excited to join the Mucosis management team. The company has made great progress to date and is now ready to move to broadening market awareness of its technology platform and vaccine pipeline.”

Advertisement